IL1B and lung carcinoma: Along with the primary observation that rates of cardiovascular events were lower in canakinumab-treated patients compared to the placebo group, further investigations revealed that IL-1ß antagonism reduced the incidence of lung cancer and cancer-related mortality (15), accentuating convergence in IL-1ß biology in CVD and cancer.